Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance

Mannan Nouri, Josselin Caradec, Amy Anne Lubik, Na Li, Brett G. Hollier, Mandeep Takhar, Manuel Altimirano-Dimas, Mengqian Chen, Mani Roshan-Moniri, Miriam Butler, Melanie Lehman, Jennifer Bishop, Sarah Truong, Shih Chieh Huang, Dawn Cochrane, Michael Cox, Colin Collins, Martin Gleave, Nicholas Erho, Mohamed Alshalafa & 7 others Elai Davicioni, Colleen Nelson, Sheryl Gregory-Evans, Robert Jeffrey Karnes, Robert Brian Jenkins, Eric A. Klein, Ralph Buttyan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Treatment-induced neuroendocrine transdifferentiation (NEtD) complicates therapies for metastatic prostate cancer (PCa). Based on evidence that PCa cells can transdifferentiate to other neuroectodermally-derived cell lineages in vitro, we proposed that NEtD requires first an intermediary reprogramming to metastable cancer stem-like cells (CSCs) of a neural class and we demonstrate that several different AR+/PSA+ PCa cell lines were efficiently reprogrammed to, maintained and propagated as CSCs by growth in androgen-free neural/neural crest (N/NC) stem medium. Such reprogrammed cells lost features of prostate differentiation; gained features of N/NC stem cells and tumor-initiating potential; were resistant to androgen signaling inhibition; and acquired an invasive phenotype in vitro and in vivo. When placed back into serum-containing mediums, reprogrammed cells could be redifferentiated to N-/NC-derived cell lineages or return back to an AR+ prostate-like state. Once returned, the AR+ cells were resistant to androgen signaling inhibition. Acute androgen deprivation or anti-androgen treatment in serum-containing medium led to the transient appearance of a sub-population of cells with similar characteristics. Finally, a 132 gene signature derived from reprogrammed PCa cell lines distinguished tumors from PCa patients with adverse outcomes. This model may explain neural manifestations of PCa associated with lethal disease. The metastable nature of the reprogrammed stem-like PCa cells suggests that cycles of PCa cell reprogramming followed by re-differentiation may support disease progression and therapeutic resistance. The ability of a gene signature from reprogrammed PCa cells to identify tumors from patients with metastasis or PCa-specific mortality implies that developmental reprogramming is linked to aggressive tumor behaviors.

Original languageEnglish (US)
Pages (from-to)18949-18967
Number of pages19
JournalOncotarget
Volume8
Issue number12
DOIs
StatePublished - 2017

Fingerprint

Cell- and Tissue-Based Therapy
Prostatic Neoplasms
Androgens
Therapeutics
Neoplastic Stem Cells
Neural Crest
Cell Lineage
Prostate
Neural Stem Cells
Tumor Cell Line
Serum
Genes
Disease Progression
Neoplasms
Cell Cycle
Neoplasm Metastasis
Phenotype
Cell Line
Mortality
Growth

Keywords

  • Cancer stem cell
  • Hormone resistance
  • Neural crest
  • Neuroendocrine transdifferentiation
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Nouri, M., Caradec, J., Lubik, A. A., Li, N., Hollier, B. G., Takhar, M., ... Buttyan, R. (2017). Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget, 8(12), 18949-18967. https://doi.org/10.18632/oncotarget.14850

Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. / Nouri, Mannan; Caradec, Josselin; Lubik, Amy Anne; Li, Na; Hollier, Brett G.; Takhar, Mandeep; Altimirano-Dimas, Manuel; Chen, Mengqian; Roshan-Moniri, Mani; Butler, Miriam; Lehman, Melanie; Bishop, Jennifer; Truong, Sarah; Huang, Shih Chieh; Cochrane, Dawn; Cox, Michael; Collins, Colin; Gleave, Martin; Erho, Nicholas; Alshalafa, Mohamed; Davicioni, Elai; Nelson, Colleen; Gregory-Evans, Sheryl; Karnes, Robert Jeffrey; Jenkins, Robert Brian; Klein, Eric A.; Buttyan, Ralph.

In: Oncotarget, Vol. 8, No. 12, 2017, p. 18949-18967.

Research output: Contribution to journalArticle

Nouri, M, Caradec, J, Lubik, AA, Li, N, Hollier, BG, Takhar, M, Altimirano-Dimas, M, Chen, M, Roshan-Moniri, M, Butler, M, Lehman, M, Bishop, J, Truong, S, Huang, SC, Cochrane, D, Cox, M, Collins, C, Gleave, M, Erho, N, Alshalafa, M, Davicioni, E, Nelson, C, Gregory-Evans, S, Karnes, RJ, Jenkins, RB, Klein, EA & Buttyan, R 2017, 'Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance', Oncotarget, vol. 8, no. 12, pp. 18949-18967. https://doi.org/10.18632/oncotarget.14850
Nouri, Mannan ; Caradec, Josselin ; Lubik, Amy Anne ; Li, Na ; Hollier, Brett G. ; Takhar, Mandeep ; Altimirano-Dimas, Manuel ; Chen, Mengqian ; Roshan-Moniri, Mani ; Butler, Miriam ; Lehman, Melanie ; Bishop, Jennifer ; Truong, Sarah ; Huang, Shih Chieh ; Cochrane, Dawn ; Cox, Michael ; Collins, Colin ; Gleave, Martin ; Erho, Nicholas ; Alshalafa, Mohamed ; Davicioni, Elai ; Nelson, Colleen ; Gregory-Evans, Sheryl ; Karnes, Robert Jeffrey ; Jenkins, Robert Brian ; Klein, Eric A. ; Buttyan, Ralph. / Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. In: Oncotarget. 2017 ; Vol. 8, No. 12. pp. 18949-18967.
@article{82000b0de0154661bd8dc7faf13a12a9,
title = "Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance",
abstract = "Treatment-induced neuroendocrine transdifferentiation (NEtD) complicates therapies for metastatic prostate cancer (PCa). Based on evidence that PCa cells can transdifferentiate to other neuroectodermally-derived cell lineages in vitro, we proposed that NEtD requires first an intermediary reprogramming to metastable cancer stem-like cells (CSCs) of a neural class and we demonstrate that several different AR+/PSA+ PCa cell lines were efficiently reprogrammed to, maintained and propagated as CSCs by growth in androgen-free neural/neural crest (N/NC) stem medium. Such reprogrammed cells lost features of prostate differentiation; gained features of N/NC stem cells and tumor-initiating potential; were resistant to androgen signaling inhibition; and acquired an invasive phenotype in vitro and in vivo. When placed back into serum-containing mediums, reprogrammed cells could be redifferentiated to N-/NC-derived cell lineages or return back to an AR+ prostate-like state. Once returned, the AR+ cells were resistant to androgen signaling inhibition. Acute androgen deprivation or anti-androgen treatment in serum-containing medium led to the transient appearance of a sub-population of cells with similar characteristics. Finally, a 132 gene signature derived from reprogrammed PCa cell lines distinguished tumors from PCa patients with adverse outcomes. This model may explain neural manifestations of PCa associated with lethal disease. The metastable nature of the reprogrammed stem-like PCa cells suggests that cycles of PCa cell reprogramming followed by re-differentiation may support disease progression and therapeutic resistance. The ability of a gene signature from reprogrammed PCa cells to identify tumors from patients with metastasis or PCa-specific mortality implies that developmental reprogramming is linked to aggressive tumor behaviors.",
keywords = "Cancer stem cell, Hormone resistance, Neural crest, Neuroendocrine transdifferentiation, Prostate cancer",
author = "Mannan Nouri and Josselin Caradec and Lubik, {Amy Anne} and Na Li and Hollier, {Brett G.} and Mandeep Takhar and Manuel Altimirano-Dimas and Mengqian Chen and Mani Roshan-Moniri and Miriam Butler and Melanie Lehman and Jennifer Bishop and Sarah Truong and Huang, {Shih Chieh} and Dawn Cochrane and Michael Cox and Colin Collins and Martin Gleave and Nicholas Erho and Mohamed Alshalafa and Elai Davicioni and Colleen Nelson and Sheryl Gregory-Evans and Karnes, {Robert Jeffrey} and Jenkins, {Robert Brian} and Klein, {Eric A.} and Ralph Buttyan",
year = "2017",
doi = "10.18632/oncotarget.14850",
language = "English (US)",
volume = "8",
pages = "18949--18967",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "12",

}

TY - JOUR

T1 - Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance

AU - Nouri, Mannan

AU - Caradec, Josselin

AU - Lubik, Amy Anne

AU - Li, Na

AU - Hollier, Brett G.

AU - Takhar, Mandeep

AU - Altimirano-Dimas, Manuel

AU - Chen, Mengqian

AU - Roshan-Moniri, Mani

AU - Butler, Miriam

AU - Lehman, Melanie

AU - Bishop, Jennifer

AU - Truong, Sarah

AU - Huang, Shih Chieh

AU - Cochrane, Dawn

AU - Cox, Michael

AU - Collins, Colin

AU - Gleave, Martin

AU - Erho, Nicholas

AU - Alshalafa, Mohamed

AU - Davicioni, Elai

AU - Nelson, Colleen

AU - Gregory-Evans, Sheryl

AU - Karnes, Robert Jeffrey

AU - Jenkins, Robert Brian

AU - Klein, Eric A.

AU - Buttyan, Ralph

PY - 2017

Y1 - 2017

N2 - Treatment-induced neuroendocrine transdifferentiation (NEtD) complicates therapies for metastatic prostate cancer (PCa). Based on evidence that PCa cells can transdifferentiate to other neuroectodermally-derived cell lineages in vitro, we proposed that NEtD requires first an intermediary reprogramming to metastable cancer stem-like cells (CSCs) of a neural class and we demonstrate that several different AR+/PSA+ PCa cell lines were efficiently reprogrammed to, maintained and propagated as CSCs by growth in androgen-free neural/neural crest (N/NC) stem medium. Such reprogrammed cells lost features of prostate differentiation; gained features of N/NC stem cells and tumor-initiating potential; were resistant to androgen signaling inhibition; and acquired an invasive phenotype in vitro and in vivo. When placed back into serum-containing mediums, reprogrammed cells could be redifferentiated to N-/NC-derived cell lineages or return back to an AR+ prostate-like state. Once returned, the AR+ cells were resistant to androgen signaling inhibition. Acute androgen deprivation or anti-androgen treatment in serum-containing medium led to the transient appearance of a sub-population of cells with similar characteristics. Finally, a 132 gene signature derived from reprogrammed PCa cell lines distinguished tumors from PCa patients with adverse outcomes. This model may explain neural manifestations of PCa associated with lethal disease. The metastable nature of the reprogrammed stem-like PCa cells suggests that cycles of PCa cell reprogramming followed by re-differentiation may support disease progression and therapeutic resistance. The ability of a gene signature from reprogrammed PCa cells to identify tumors from patients with metastasis or PCa-specific mortality implies that developmental reprogramming is linked to aggressive tumor behaviors.

AB - Treatment-induced neuroendocrine transdifferentiation (NEtD) complicates therapies for metastatic prostate cancer (PCa). Based on evidence that PCa cells can transdifferentiate to other neuroectodermally-derived cell lineages in vitro, we proposed that NEtD requires first an intermediary reprogramming to metastable cancer stem-like cells (CSCs) of a neural class and we demonstrate that several different AR+/PSA+ PCa cell lines were efficiently reprogrammed to, maintained and propagated as CSCs by growth in androgen-free neural/neural crest (N/NC) stem medium. Such reprogrammed cells lost features of prostate differentiation; gained features of N/NC stem cells and tumor-initiating potential; were resistant to androgen signaling inhibition; and acquired an invasive phenotype in vitro and in vivo. When placed back into serum-containing mediums, reprogrammed cells could be redifferentiated to N-/NC-derived cell lineages or return back to an AR+ prostate-like state. Once returned, the AR+ cells were resistant to androgen signaling inhibition. Acute androgen deprivation or anti-androgen treatment in serum-containing medium led to the transient appearance of a sub-population of cells with similar characteristics. Finally, a 132 gene signature derived from reprogrammed PCa cell lines distinguished tumors from PCa patients with adverse outcomes. This model may explain neural manifestations of PCa associated with lethal disease. The metastable nature of the reprogrammed stem-like PCa cells suggests that cycles of PCa cell reprogramming followed by re-differentiation may support disease progression and therapeutic resistance. The ability of a gene signature from reprogrammed PCa cells to identify tumors from patients with metastasis or PCa-specific mortality implies that developmental reprogramming is linked to aggressive tumor behaviors.

KW - Cancer stem cell

KW - Hormone resistance

KW - Neural crest

KW - Neuroendocrine transdifferentiation

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85015764709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015764709&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14850

DO - 10.18632/oncotarget.14850

M3 - Article

VL - 8

SP - 18949

EP - 18967

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -